

O  
JUN 2002  
PATENT & TRADEMARK OFFICE

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DKT. NO. BAYER 15P4	SERIAL NO. 10/071,248
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT Jacques Dumas and William J. Scott	
				FILING DATE February 11, 2002	GROUP 1625

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date
RO	AA	502,504	8/1/1893	Thoms		
RO	AB	1,742,156	2/31/2002	Fritzky		
RO	AC	2,046,375	7/36	Goldstein et al.		
RO	AD	2,093,265	9/30/2002	Coffby et al.		
RO	AE	2,288,422	6/42	Rohm		
RO	AF	2,649,476	8/18/53	Martin		
RO	AG	2,683,082	7/54	Hill et al.		
RO	AH	2,722,544	11/1/55	Martin		
RO	AI	2,745,874	5/56	Schetty et al.		
RO	AJ	2,781,330	2/57	Downey		
RO	AK	2,797,214	6/25/57	Werner Bossard		
RO	AL	2,867,659	1/59	Model et al.		
RO	AM	2,877,268	3/59	Applegate et al.		
RO	AN	2,960,488	11/60	Tamblyn et al.		
RO	AO	2,973,386	2/61	Weldon		
RO	AP	3,151,023	9/64	Martin		
RO	AQ	3,200,035	8/65	Martin et al.		
RO	AR	3,230,141	1/66	Frick et al.		
RO	AS	3,424,760	01/28/69	Helsley et al.		
RO	AT	3,424,761	01/28/69	Helsley et al.		
RO	AU	3,424,762	01/28/69	Helsley et al.		
RO	AV	3,547,940	12/15/70	Brantley		
RO	AW	3,646,059	02/29/72	Brantley		
RO	AX	3,689,550	9/72	Schellenbaum et al.		
RO	AY	3,743,498	7/3/73	Brantley		
RO	AZ	3,754,887	08/28/73	Brantley		
RO	BA	3,823,161	07/09/74	Lesser		
RO	BB	3,828,001	8/74	Broad et al.		
RO	BC	3,860,645	1/95/2002	Nikawitz		
RO	BD	3,990,879	11/9/1976	Soper		
RO	BE	4,001,256	1/4/97/2002	Callahan et al.		
RO	BF	4,009,847	3/1/77	Aldrich et al.		
RO	BG	4,042,372	8/16/1977	Harper		
RO	BH	4,062,861	12/13/77	Yukinaga et al.		
RO	BI	4,071,524	01/31/78	Banitt		
RO	BJ	4,111,680	09/05/78	Yukinaga et al.		

RECEIVED  
TECH CENTER 1600/2000  
OCT 24 2002

015  
JC98  
JUN 10 2002

10/04/2002

RP	BK	4,111,683	09/05/78	Singer			
RP	BL	4,116,671	09/26/78	Yukinaga et al.			
RP	BM	4,173,637	11/79	Nishiyama et al.			
RP	BN	4,173,638	11/79	Nishiyama et al.			
RP	BO	4,183,854	1/80	Crossley			
RP	BP	4,212,981	07/15/80	Yukinaga et al.			
RP	BQ	4,240,820	12/23/80	Dickore et al.			
RP	BR	4,405,644	9/20/83	Kabbe et al.			
RP	BS	4,410,697	10/18/83	Török et al.			
RP	BT	4,437,878	03/20/84	Acker et al.			
RP	BU	4,468,380	8/28/84	O'Doherty et al.			
RP	BV	4,473,579	9/25/84	Devries et al.			
RP	BW	4,511,571	4/85	Böger et al.			
RP	BX	4,514,571	04/30/85	Nakai et al.			
RP	BY	4,526,997	7/2/85	O'Doherty et al.			
RP	BZ	4,623,662	11/18/86	De Vries			
RP	CA	4,643,849	02/17/87	Hirai et al.			
RP	CB	4,740,520	4/88	Hallenbach et al.			
RP	CC	4,760,063	7/26/88	Hallenbach et al.			
RP	CD	4,808,588	02/28/89	King			
RP	CE	4,820,871	4/89	Kissener et al.			
RP	CF	4,863,924	9/89	Haga et al.			
RP	CG	4,983,605	1/91	Kondo et al.			
RP	CH	4,985,449	1/15/91	Haga et al.			
RP	CI	5,036,072	7/91	Nakajama et al.			
RP	CJ	5,059,614	10/22/91	Lepage et al.			
RP	CK	5,098,907	3/92	Kondo et al.			
RP	CL	5,130,331	07/14/92	Pascual			
RP	CM	5,162,360	11/10/92	Creswell et al.			
RP	CN	5,185,358	2/9/1993	Creswell			
RP	CO	5,312,820	5/17/94	Ashton et al.			
RP	CP	5,319,099	6/7/94	Kamata et al.			
RP	CQ	5,399,566	3/21/95	Katano et al.			
RP	CR	5,423,905	6/95	Fringeli			
RP	CS	5,429,918	7/4/1995	Seto et al.			
RP	CT	5,432,468	7/11/95	Moriyama et al.			
RP	CU	5,470,882	11/95	Dixon et al.			
RP	CV	5,500,424	3/19/96	Nagamine et al.			
RP	CW	5,508,288	04/16/96	Forbes et al.			
RP	CX	5,597,719	1/28/97	Freed et al.			
RP	CY	5,696,138	12/9/97	Olesen et al.			
RP	CZ	5,698,581	12/16/97	Kleemann et al.			
RP	DA	5,773,459	06/30/98	Tang et al.			
RP	DB	5,780,483	7/14/98	Widdowson et al.			
RP	DC	5,780,483	7/14/98	Widdowson et al.			
RP	DD	5,807,891	9/15/98	Bold et al.			

RECEIVED  
TECH CENTER 10/04/2002

O I P E  
JUN 10 2002  
SEARCHED INDEXED  
SERIALIZED FILED

10/09/2002

PO	DE	5,814,646	9/29/1998	Heinz	1	1	1
PO	DF	5,886,044	3/23/99	Widdowson et al.	1	1	1
PO	DG	5,891,895	4/6/99	Shiraishi et al.	1	1	1
PO	DH	5,908,865	6/1/1999	Doi et al.	1	1	1
PO	DI	5,965,573	10/12/99	Petrie et al.	1	1	1
PO	DJ	6,004,965	12/21/99	Breu et al.	1	1	1
PO	DK	6,005,008	12/21/99	Widdowson et al.	1	1	1
PO	DL	6,020,345	2/1/00	Vacher et al.	1	1	1
PO	DM	6,040,339	3/21/00	Yoshida et al.	1	1	1
PO	DN	6,080,763	6/27/2000	Regan et al.	1	1	1
PO	DO	6,093,742	7/25/00	Salituro et al.	1	1	1
PO	DP	6,133,319	10/17/00	Widdowson	1	1	1
PO	DQ	6,150,415	11/21/00	Hammock et al.	1	1	1
PO	DR	6,174,901B1	1/16/01	Mantlo et al.	1	1	1
PO	DS	6,178,399B1	1/23/01	Takebayashi et al.	1	1	1
PO	DT	6,180,675B1	1/30/01	Widdowson et al.	1	1	1
PO	DU	6,187,799B1	2/13/01	Wood et al.	1	1	1
PO	DV	6,211,373B1	4/3/01	Widdowson et al.	1	1	1
PO	DW	6,218,539B1	4/17/01	Widdowson et al.	1	1	1
PO	DX	6,242,601B1	6/5/01	Breu et al.	1	1	1
PO	DY	6,262,113B1	7/17/01	Widdowson et al.	1	1	1
PO	DZ	6,271,261B1	8/7/01	Widdowson	1	1	1
PO	EA	6,333,341B1	12/25/01	Mantlo et al.	1	1	1
PO	EB	6,339,045B1	1/15/02	Kanno et al.	1	1	1

RECEIVED

TECH CENTER 1600/2900

OCT 24 2002

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
PO	EC	90/02112	3/8/90	WO			
PO	ED	93/18028	09/16/93	WO			
PO	EE	93/24458	12/9/93	WO			
PO	EF	94/14801	07/07/94	WO			
PO	EG	94/22807	10/13/94	WO			
PO	EH	94/18170	08/18/94	WO			
PO	EI	94/25012	11/10/94	WO			
PO	EJ	95/02591	01/26/95	WO			
PO	EK	95/07922	03/23/95	WO			
PO	EL	95/13067	05/18/95	WO			
PO	EM	95/31451	11/23/95	WO			
PO	EN	95/33458	12/14/95	WO			
PO	EO	96/10559	4/11/96	WO			
PO	EP	96/25157 A1	8/22/96	WO			
PO	EQ	96/40673	12/19/96	WO			
PO	ER	96/40675 A1	12/19/96	WO			
PO	ES	97/17329	5/15/97	WO			



10/04/2002

RECEIVED  
16/01/2000

PO	ET	97/29743	8/21/97	WO				
PO	EU	97/30992	8/28/97	WO				
PO	EV	97/40028 A1	10/30/97	WO				
PO	EW	97/49400	12/31/97	WO				
PO	EX	97/49399	12/31/97	WO				
PO	EY	97/45400	12/4/97	WO				
PO	EZ	98/17267	4/30/98	WO				
PO	FA	98/22103	5/28/1998	WO				
PO	FB	98/22432	5/28/98	WO				
PO	FC	98/52558	11/26/98	WO				
PO	FD	98/52559	11/26/98	WO				
PO	FE	99/00357	1/7/99	WO				
PO	FF	99/00370	1/7/99	WO				
PO	FG	99/23091	5/14/99	WO				
PO	FH	99/24398	5/20/99	WO				
PO	FI	99/32106	7/1999	WO				
PO	FJ	99/32110	7/1/99	WO				
PO	FK	99/32111	7/1/1999	WO				
PO	FL	99/32436	7/1/99	WO				
PO	FM	99/32437	7/1/99	WO				
PO	FN	99/32455	7/1/1999	WO				
PO	FO	99/32463	7/1/99	WO				
PO	FP	99/33458	7/8/99	WO				
PO	FQ	99/40673	8/12/99	WO				
PO	FR	00/17175	3/30/2000	WO				
PO	FS	00/43366A1	01/20/2000	WO				
PO	FT	00/43384	7/27/2000	WO				
PO	FU	00/55139	9/21/2000	WO				
PO	FV	00/55152	9/21/2000	WO				
PO	FW	0016371A1	3/5/80	EP				
PO	FX	0 405 233	1/91	EP				
PO	FY	0116932	8/29/84	EP				
PO	FZ	242666	10/28/87	EP				
PO	GA	335156	03/11/89	EP				
PO	GB	371876	11/28/89	EP				
PO	GC	425443A1	2/5/91	EP				
PO	GD	459887	05/28/91	EP				
PO	GE	676395	7/17/1996	EP				
PO	GF	0202538A1	11/26/86	EP				
PO	CG	860433A1	8/26/98	EP				
PO	GH	0 523 437	5/31	Germany				
PO	GI	0 511 468	10/30	Germany				
PO	GJ	0 487 014	12/29	Germany				
PO	GK	0 253 997	2/88	East Germany				
PO	GL	2436179A1	2/6/1975	DE				

JUN 10 2002

10/07/2002

PO	GM	2436179C2	2/6/75	DE			
PO	GN	25 01 648	7/24/75	DE			
PO	GO	35 40 377 A1	11/14/85	DE			
PO	GP	35 29 247 A1	8/20/85	DE			
PO	GQ	3305866A1	02/19/83	DE			
PO	GR	3 532 47	3/91	Japan			
PO	GS	8 031841	11/19/96	Japan			
PO	GT	44 2569	2/69	Japan			
PO	GU	10-306078	11/17/98	Japan			
PO	GV	50-149668	11/75	Japan			
PO	GW	50-76072	6/75	Japan			
PO	GX	50-77375	6/75	Japan			
PO	GY	51 063170	1/6/76	Japan			
PO	GZ	51-80862	7/76	Japan			
PO	HA	53 086033	7/29/78	Japan			
PO	HB	55 98152	7/80	Japan			
PO	HD	55-124763	9/80	Japan			
PO	HE	55-162772	12/80	Japan			
PO	HF	0 771 333	3/57	Great Britain			
PO	HG	0 828 231	10/56	Great Britain			
PO	HH	0 921 682	3/63	Great Britain			
PO	HI	1,590,870	06/10/81	Great Britain			
PO	HJ	1 457 172	9/66	France			
PO	HK	2,146,707	10/12/95	Canada			

RECEIVED  
TECH CENTER 1600/2900  
07/24/2002

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

PO	HL	Caplus 86:72448, Abstract JP 57053785, Pyridine derivatives, Maeda Ryozo et al., November 15, 1982
PO	HM	Caplus 84:180049, Abstract JP 56029871, Hamada Yoshinori et al., July 10, 1981
PO	HN	Caplus 84:43857, Abstract JP 58021626, Maeda Ryozo et al., May 2, 1983
PO	HO	Caplus 95:61995, Abstract JP 55162772, Substituted acetic derivatives, Shionogi & Co., May 23, 1980
PO	HP	Abstract of EP 202,538
PO	HQ	Abstract of DE 3305866 (EP equivalent 116,932)
PO	HR	Abstract of EP 116,932
PO	HS	Abstract of EP 16,371
PO	HT	Abstract of EP 4931A equivalent 4,240,820)
PO	HU	Abstract of EP 676,395 (U.S. equivalent 5,698,581)
PO	HV	Abstract WO 9822103, Hedge 28 May 1998
PO	HW	Chemical Abstract, Vol. 116, No. 21, 25 May 1992, pages 741-742
PO	HX	Tarzia, G. et al., "Whythesis and anit-inflammatory properties of some pyrrolo(1H,3H)-[3,4]pyrimidin-2-ones and pyrrolo(1H,3H)[3,4-d]pyrimidin-2-ones and pyrrolo(1H,3H)-pyrimidin-2-ones. Chemical Abstracts. 27 August 1979, No. 74558p; page 594.
PO	HY	White, A. D., et al., "Heterocyclic Ureas: Inhibitors of Acyl-CoA:Cholesterol <i>O</i> -Acyltransferase as Hypocholesterolemic Agents," June 6, 1996, pages 4382-95.



10/09/248

Ro	HZ	Audia, James E., et al., "Potent, Selective Tetrahydro- $\beta$ -carboline Antagonists of the Serotonin 2B (5-HT <sub>2B</sub> ) Contractile Receptor in the Rat Stomach Fundus," January 22, 1996, pages 2773-80.
Ro	IA	Forbes, Ian T., "N-(1-Methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea: A Novel, High-Affinity 5-HT <sub>2B</sub> Receptor Antagonist," March 17, 1995, pages 855-57.
Ro	IB	Boulton, A. J., et al., "Heterocyclic Rearrangements. Part X. <sup>1</sup> A Generalised Monocyclic Rearrangement," 1967, 2005-07.
Ro	IC	W. Kolch, et al., "Raf-1 protein kinase is required for growth of induced NIH/3T3 cells," Letters to Nature, vol. 349, January 31, 1991, page 226-28.
Ro	ID	M. Fridman, et al., "The Minimal Fragments of c-Raf-1 and NF1 That Can Suppress v-Ha-Ras-Induced Malignant Phenotype," The Journal of Biological Chemistry, vol. 269, no. 48, December 2, 1994, pages 30105-108.
Ro	IE	G. L. Bolton, et al., Chapter 17. Ras Oncogene Directed Approaches in Cancer Chemotherapy, Annual Reports In Medicinal Chemistry, vol. 29, 1994, pages 165-74.
Ro	IF	J. L. Bos, "ras Oncogenes in Human Cancer: A Review," Cancer Research, vol. 49, September 1, 1989, pages 4682-89.
Ro	IG	Michaelis, Justus, Liebigs Ann. Chem. (JLACBF) 397, 1913, 143.
Ro	IH	B. P. Monia, et al., "Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase," Nature Medicine, vol. 2, No. 6, June 1996, pages 668-75.
Ro	II	Lee, et al., Bicyclic Imidazoles as a Novel Class of Cytokine Biosynthesis Inhibitors," N.Y. Academy of Science, 1993, pages 149-70.
Ro	IJ	F. Lepage, et al., "New N-aryl isoxazolecarboxamides and N-isoxazolybenzamides as anticonvulsant agents," Eur. J. Med. Chem, vol. 27, 1992, pages 581-93.
Ro	IK	Ridley, et al., "Actions of IL-1 are Selectively Controlled by p38 Mitogen-Activated Protein Kinase," The American Association of Immunologists, 1997, page 3165-73.
Ro	IL	N. S. Magnuson, et al., "The Raf-1 serine/threonine protein kinase," Cancer Biology, vol. 5, 1994, pages 247-253.
Ro	IM	G. Daum, et al., The ins and outs of Raf Kinases,: TIBS 19, November 1994, pages 474-80.
Ro	IN	Grant, A.M. et al.: "Hypotensive thiadiazoles" J. Med. Chem. (1972), 15(10), 1082-4.
Ro	IO	Russo, F. et al. "Synthesis of 2,6-substituted derivatives of 5H-1,3,4-thiadiazolo'3,2-a'-s triazine-5,7-dione" FARMACO, ED.SCI. (1978), 33(12), 972-83
Ro	IP	Joseph T. Bruder and Imre Kovesdi, "Adenovirus Infection Stimulates the Raf/MAPK Signaling Pathway and Induces Interleukin-8 Expression, May 17, 1996, pp. 198-404.
Ro	IQ	Foussard-Blanpin, Odette: "Comparative pharmacodynamic study of variously substituted carboxamides of the central nervous system" Ann. Pharm. Fr. (1982), 40 (4), 339-50
Ro	IR	Kubo, Hiroshi et al. "Herbicidal activity of 1,3,4-thiadiazole derivatives" J. Agr. Food Chem. (1970) , 18(1), 60-5
Ro	IS	Avruch et al., "Raf meets Ras: completing the framework of a signal transduction pathway", TIBS 19; July 1994; pp. 279-2823.
.	IT	
.	IU	
.	IV	
.	IW	
.	IX	
.	IY	
.	IZ	

RECEIVED  
OCT 24 2002  
TECH CENTER 1600/2001

Examiner

R Desai

**Date Considered**

1-2-9-2007

\*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.